Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RN0191
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : LongRiver Investments
Deal Size : $35.0 million
Deal Type : Series A Financing
Rona Therapeutics Raises $35M Series A+ to Advance Innovative Metabolic siRNA Pipeline
Details : The financing aims to fund the clinical development of the company's first program RN0191, a best-in-class PCSK9 siRNA program, which is being evaluated for treating Hypercholesteremia.
Brand Name : RN0191
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 19, 2024
Lead Product(s) : RN0191
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : LongRiver Investments
Deal Size : $35.0 million
Deal Type : Series A Financing
Lead Product(s) : siRNA Therapeutic
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Recipient : Sanofi
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Rona licensed Sanofi’s siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neuro and muscular disease candidates for ex-China territories.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 25, 2022
Lead Product(s) : siRNA Therapeutic
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Recipient : Sanofi
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : RNA Therapeutic
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Lilly Asia Ventures
Deal Size : $33.0 million
Deal Type : Series A Financing
Details : The RNA medicines from Rona Therapeutics are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 07, 2022
Lead Product(s) : RNA Therapeutic
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Lilly Asia Ventures
Deal Size : $33.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?